Over the past two decades, monoclonal antibodies (mAbs) have played a pivotal role in cancer treatment; however, their efficacy as anticancer agents is constrained by tumor heterogeneity and the ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender ...

and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at simultaneously engaging multiple targets, promising improved efficacy and safety ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A ...

Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities EP: 15 . Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...